SYNDAX PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.06 USD | +2.38% |
|
+1.25% | -2.55% |
Presenter SpeechYigal Nochomovitz (Analysts)Hi. Welcome back, everyone, to the next session of...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing pipeline of cancer therapies. Its product candidates include revumenib, and axatilimab. It is developing revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant A. It is also exploring the use of revumenib as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.
Calendar
2024-05-05
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
21.06
USD
Average target price
35.17
USD
Spread / Average Target
+66.98%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -2.55% | 1.79B | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- SNDX Stock
- News Syndax Pharmaceuticals, Inc.
- Transcript : Syndax Pharmaceuticals, Inc. Presents at Citi 2024 Virtual Oncology Leadership Summit, Feb-21-2024 11
